Trade Summary

3 days ago, Eisner Mark, serving as EVP, Chief Medical Officer at Vir Biotechnology, Inc. (VIR), sold 3,505 shares at $9.69 per share, for a total transaction value of $33,955.00. Following this transaction, Eisner Mark now holds 154,024 shares of VIR.

This sale represents a 2.00% decrease in Eisner Mark's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, February 24, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 26, 2026, 2 days after the trade was made.

Vir Biotechnology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.